参考文献/References:
[1] Saeedi P,Petersohn I,Salpea P,et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:results from the International Diabetes Federation Diabetes Atlas,9(th)edition [J].Diabetes Res Clin Pract,2019,157:107843.DOI:10.1016/j.diabres.2019.107843.
[2] Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study [J].BMJ,2020,369:m997.DOI:10.1136/bmj.m997.
[3] World Alzheimer report 2018[DB/OL].London:Alzheimer's Disease Internation(API).2018[2021-02-20].https://www.alzint.org/resource/world-alzheimer-report-2018/.
[4] Akomolafe A,Beiser A,Meigs JB,et al.Diabetes mellitus and risk of developing Alzheimer disease:results from the Framingham Study [J].Arch Neurol,2006,63(11):1551-1555.DOI:10.1001/archneur.63.11.1551.
[5] Cukierman T,Gerstein HC,Williamson JD.Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies [J].Diabetologia,2005,48(12):2460-2469.DOI:10.1007/s00125-005-0023-4.
[6] Cheng G,Huang C,Deng H,et al.Diabetes as a risk factor for dementia and mild cognitive impairment:a meta-analysis of longitudinal studies [J].Intern Med J,2012,42(5):484-491.DOI:10.1111/j.1445-5994.2012.02758.x.
[7] De Felice FG,Ferreira ST.Inflammation,defective insulin signaling,and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease [J].Diabetes,2014,63(7):2262-2272.DOI:10.2337/db13-1954.
[8] Kim JY,Ku YS,Kim HJ,et al.Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes [J].Diabetes Res Clin Pract,2019,154:116-123.DOI:10.1016/j.diabres.2019.07.004.
[9] Samaras K,Makkar S,Crawford JD,et al.Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes:the Sydney Memory and Ageing Study [J].Diabetes Care,2020,43(11):2691-2701.DOI:10.2337/dc20-0892.
[10] Chin-Hsiao T.Metformin and the risk of dementia in type 2 diabetes patients [J].Aging Dis,2019,10(1):37-48.DOI:10.14336/AD.2017.1202.
[11] Imfeld P,Bodmer M,Jick SS,et al.Metformin,other antidiabetic drugs,and risk of Alzheimer's disease:a population-based case-control study [J].J Am Geriatr Soc,2012,60(5):916-921.DOI:10.1111/j.1532-5415.2012.03916.x.
[12] Heneka MT,Fink A,Doblhammer G.Effect of pioglitazone medication on the incidence of dementia [J].Ann Neurol,2015,78(2):284-294.DOI:10.1002/ana.24439.
[13] Chou PS,Ho BL,Yang YH.Effects of pioglitazone on the incidence of dementia in patients with diabetes [J].J Diabetes Complications,2017,31(6):1053-1057.DOI:10.1016/j.jdiacomp.2017.01.006.
[14] Lu CH,Yang CY,Li CY,et al.Lower risk of dementia with pioglitazone,compared with other second-line treatments,in metformin-based dual therapy:a population-based longitudinal study [J].Diabetologia,2018,61(3):562-573.DOI:10.1007/s00125-017-4499-5.
[15] Cheng C,Lin CH,Tsai YW,et al.Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis [J].J Gerontol A Biol Sci Med Sci,2014,69(10):1299-1305.DOI:10.1093/gerona/glu073.
[16] Wium-Andersen IK,Osler M,Jørgensen MB,et al.Antidiabetic medication and risk of dementia in patients with type 2 diabetes:a nested case-control study [J].Eur J Endocrinol,2019,181(5):499-507.DOI:10.1530/EJE-19-0259.
[17] Hsu CC,Wahlqvist ML,Lee MS,et al.Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin [J].J Alzheimers Dis,2011,24(3):485-493.DOI:10.3233/JAD-2011-101524.
[18] Chen KC,Chung CH,Lu CH,et al.Association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in Taiwan [J].J Clin Med,2020,9(3):660.DOI:10.3390/jcm9030660.
[19] Kim YG,Jeon JY,Kim HJ,et al.Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase Ⅳ inhibitors versus sulfonylureas:a real-world population-based cohort study [J].J Clin Med,2018,8(1):28.DOI:10.3390/jcm8010028.
[20] Tseng CH.Dementia risk in type 2 diabetes patients:acarbose use and its joint effects with metformin and pioglitazone [J].Aging Dis,2020,11(3):658-667.DOI:10.14336/AD.2019.0621.
[21] Huang CC,Chung CM,Leu HB,et al.Diabetes mellitus and the risk of Alzheimer's disease:a nationwide population-based study [J].PLoS One,2014,9(1):e87095.DOI:10.1371/journal.pone.0087095.
[22] Markowicz-Piasecka M,Sikora J,Szydowska A,et al.Metformin-a future therapy for neurodegenerative diseases:Theme:Drug discovery,development and delivery in Alzheimer's Disease guest editor:Davide Brambilla [J].Pharm Res,2017,34(12):2614-2627.DOI:10.1007/s11095-017-2199-y.
[23] Daniels D,Mietlicki-Baase EG.Glucagon-like peptide 1 in the brain:where is it coming from,where is it going? [J].Diabetes,2019,68(1):15-17.DOI:10.2337/dbi18-0045.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(04):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(04):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]